House Republicans’ funding patch includes cutting funds for the Congressionally Directed Medical Research Programs, an agency ...

In our second episode of CEO to CEO: Behind the Counter, Pepper Lunch executive Troy Hooper and Cherry Bounce’s Scott Taylor quiz each other on scaling differentiated brands and what it’s like to ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Tight end Austin Hooper will remain in New England for 2025. Hooper has a one-year deal in place, ESPN’s Adam Schefter reports. The pact has a base value of $5M and can top out at $7M.

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

MIAMI - Florida Sen. Rick Scott is once again pushing for tighter sanctions on the Cuban government, including renewed restrictions on flights to the island. The Republican senator argued that U.S ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025 ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the “real culprit” for Merck shares remaining under ...